UnitedHealth’s Optum Rx PBM To Coax Patients To Less Pricey Biosimilars Of Abbvie’s Humira

UnitedHealth Group’s OptumRx PBM will put biosimilar versions of Abbvie’s expensive rheumatoid arthritis drug Humira “in the same position as the brand” on the PBM’s preferred list of drugs known as a formulary, in 2023.

Read the full post at Forbes - Healthcare
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive